Clinical
Research & Trials
We are committed to offering our patients the latest developments in medicine while also providing the highest quality patient care. One of the ways we accomplish this goal is through clinical trials. Clinical trials are at the heart of all medical advances, offering new and innovative solutions to patients that are not widely available to the public.
Current Clinical Studies
.png?width=72&height=74&name=patient-information%20(2).png)
CCM Therapy
CCM therapy is an investigational advanced treatment option currently available through clinical trials, using an implanted device designed to help improve heart function and manage heart failure symptoms.
Integra-D
This clinical trial investigates the safety and effectiveness of a new type of implantable defibrillator (ICD) called the Integra-D, a smaller and more efficient ICD designed to improve the quality of life for people with heart failure.
Impulse Dynamics
For this trial, SWCVA is collaborating with pioneering developer Impulse Dynamics. Together, we are transforming care through groundbreaking technologies like the Optimizer® Smart System and Torus2 stent graft.
Our Research
Bay Area Cardiology physicians have been participating in clinical research since 1992.
Since then we have been involved in over 90 studies both nationally and internationally. Through patient-oriented research Bay Area Cardiology seeks to improve treatments and outcomes.
Bay Area Cardiology physicians have been participating in clinical research since 1992. Since then, we have been involved in over 120 studies both nationally and internationally. Through patient-oriented research Bay Area Cardiology seeks to improve treatments and outcomes.
Bay Area Cardiology is proud of its dedicated team of four full time professionals who are experienced at coordinating trials and maintaining a high standard of quality and performance.
Our experience with clinical trials includes registries, investigational medications, FDA post market approved drugs, coronary stents, peripheral stents, carotid stents, pacemakers, Bi-V and AICD devices.
We participate in both office and hospital based studies that cover a wide variety of cardiac and vascular medicine and treatments.
Our current enrolling clinical trials include treatment of:
- Hyperlipidemia (Both elevated LDL or LPa)
- Heart Failure
- Non-Valvular Atrial Fibrillation
- Peripheral Arterial Disease
- Acute MI (Heart attack)
- COPD
Examples of Our Clinical Studies:
ADAPTA (Medtronic)
A randomized trial to compare single-chamber atrial (AAl) and Dual-chamber (DDD) pacing in patients with Sick Sinus Syndrome
– Ranked #1 out of 100 sites
– PI: Dr. Mester
RELY (Boehringer Ingelheim)
Randomized Evaluation of Outcomes of Long Term Anticoagulant therapy.
– Ranked #9 out of 952 sites
– PI: Dr. Khant
– Ranked #9 out of 952 sites
– PI: Dr. Khant
RATE (St. Jude Medical)
Registry of AT/AF Episodes in the CRM Device Population
– Ranked #5 out of 19 sites
– PI: Dr. Betzu
– Ranked #5 out of 19 sites
– PI: Dr. Betzu
PREDETERMINE (NIHL)
Markers of Sudden Cardiac Death Registry
– Ranked #6 out of 105 sites
– PI: Dr. Bugni
– Ranked #6 out of 105 sites
– PI: Dr. Bugni
TRANSLATE (DCRI)
Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome
– Ranked #55 out of 233
– PI: Dr. Rodriguez
IMPROVE-IT (Merck/Schering Plough)
Improved Reduction of Outcomes: Vytorin Efficacy International Trial
– Ranked #67 out of 359 sites
– PI: Dr. Betzu
– Ranked #67 out of 359 sites
– PI: Dr. Betzu
CAMELLIA (Eisai)
A Randomized, Double-blind, Placebo-controlled, Parallel- group Study to Evaluate the Long-term Treatment with BELVIQ (lorcaserin HCL) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.
– Ranked #3 out of 400 sites
– PI: Dr. Chokshi
– Ranked #3 out of 400 sites
– PI: Dr. Chokshi
Patient REVEAL (Merck/Oxford University)
HPS 3/ TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease.
– Ranked #61 out of 151 sites
– PI: Dr. Khan
– Ranked #61 out of 151 sites
– PI: Dr. Khan
PAH (Actelion)
Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program
– Ranked #22 out of 71 site
– PI: Dr. Dewhurst
ST SEGMENT (Medtronic)
Virtuoso Implantable Cardioverter Defibrillator ST Segment Algorithm
– Ranked #4 out of 24 sites
– PI: Dr.Mester
– Ranked #4 out of 24 sites
– PI: Dr.Mester
1160.128 (Boehringer Ingelheim)
A prospective, open-label study evaluating the efficacy of two management strategies (pantoprazole 40 mg q a.m. and taking Pradaxa with food (within 30 minutes after a meal)) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa 150 mg b.i.d. or 75 mg b.i.d. for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
– Ranked #4 out of 26 sites
– PI: Dr. Khant
– Ranked #4 out of 26 sites
– PI: Dr. Khant
EFFECT-AF (Laser)
An Atrial Fibrillation treatment registry
– Ranked #12 out of 54
– PI: Dr. Perzanowski
– Ranked #12 out of 54
– PI: Dr. Perzanowski